Sao Mamede do Coronado, Portugal

Francisco Cardona

This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Bial-Portela Ca & S.a.. Active years: 2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Francisco Cardona. Retrieved from https://idiyas.com/inventor/francisco-cardona

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2022

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Francisco Cardona: Innovator in Dopamine-b-Hydroxylase Inhibitors

Introduction

Francisco Cardona is a notable inventor based in Sao Mamede do Coronado, Portugal. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that serve as dopamine-β-hydroxylase inhibitors. His work is crucial in advancing therapeutic methods for various medical conditions.

Latest Patents

Cardona holds a patent for his invention titled "Dopamine-b-hydroxylase inhibitors." This invention encompasses several key components: (a) compounds of formula Ia, including pharmaceutically acceptable salts or solvates that are effective as dopamine-β-hydroxylase inhibitors; (b) pharmaceutical compositions that incorporate these compounds; (c) the therapeutic use of these compounds; (d) methods of treatment utilizing these compounds; and (e) processes and intermediates for synthesizing these compounds. He has 1 patent to his name, showcasing his innovative approach to pharmaceutical development.

Career Highlights

Cardona is associated with Bial-Portela Ca & S.a., a company known for its commitment to research and development in the pharmaceutical sector. His role at the company allows him to contribute to groundbreaking research that has the potential to impact patient care positively.

Collaborations

Throughout his career, Cardona has collaborated with esteemed colleagues, including Laszlo Erno Kiss and Alexander Beliaev. These partnerships have fostered an environment of innovation and shared knowledge, further enhancing the quality of their research and development efforts.

Conclusion

Francisco Cardona's work in the field of dopamine-β-hydroxylase inhibitors exemplifies the impact of innovative thinking in pharmaceuticals. His contributions are paving the way for new therapeutic options, demonstrating the importance of research and collaboration in advancing medical science.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…